| Customization: | Available |
|---|---|
| CAS No.: | 864070-44-0 |
| Formula: | N/a |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Empagliflozin, identified by the CAS number 864070-44-0, is a medication developed for the treatment of type 2 diabetes. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which works by reducing the reabsorption of glucose by the kidneys and increasing the excretion of glucose in the urine, thereby lowering blood glucose levels. This class of drugs provides an alternative or adjunct therapy to diet and exercise for managing blood sugar in adults with type 2 diabetes mellitus .
Empagliflozin is typically administered orally and is available in tablet form, with common dosages being 10 mg or 25 mg once daily. It can be used as a monotherapy or in combination with other hypoglycemic agents such as metformin. The drug has demonstrated efficacy in improving glycemic control and has been associated with additional benefits such as weight loss and blood pressure reduction .
However, empagliflozin use has been linked to potential side effects, including an increased risk of urinary tract and genital infections due to the increased glucose in the urine. It can also cause dehydration and volume-related adverse effects, particularly in patients with impaired renal function. Additionally, there have been reports of acute kidney injury and ketoacidosis, a serious condition that requires immediate medical attention
){kind=link}